H2APEX Publishes Half-year Results 2026: Revenue up by About Two-thirds

H2APEX reported H1 2026 revenue up 67.5% to EUR 7.0 million (vs EUR 4.2 million) driven by a PMC contract for the 100MW WAL project and increased own production volumes (45 tonnes green hydrogen vs 39 tonnes). The company launched commercial revenue from its AKROS container-based salt hydrogen storage technology in May, and secured feed-in capacity for WAL into Germany’s hydrogen core network. Despite losses (adjusted EBITDA EUR -14.4 million), management confirmed 2026 revenue guidance of EUR 14 million–EUR 16 million, supported by new EU RED III binding green hydrogen demand quotas.

Analysis

The market should read this as a credibility update, not an earnings inflection. The incremental revenue mix is improving, but the company is still in the phase where higher activity tends to pull forward working capital, staffing, and project overhead faster than it creates shareholder value. That means the equity is likely to trade on financing risk and permit/execution milestones, while the operating story remains a call option on policy and grid access rather than a self-funding growth model.

The real winners are not the small hydrogen developers themselves but the toll collectors around them: industrial gas incumbents and network/infrastructure owners with balance sheets, permitting expertise, and lower cost of capital. If binding quotas lift project visibility, the first-order effect is better bankability for qualified projects; the second-order effect is margin pressure for equipment vendors and EPCs as more players chase a regulated market with standardized specs. In other words, policy can increase volume while compressing economics for the weakest links in the value chain.

Over the next 1-3 months, the key catalyst is whether this can translate into a credible funding path for the large projects. If capex, power-price assumptions, or commissioning dates slip, the stock should fade quickly because the current revenue base is too small to absorb even modest delays. Over 6-18 months, the thesis is falsified if WAL/SKY/SPARK do not reach FID or if the company needs repeated equity raises to fund ramp-up; in that case, the market will re-rate it as a dilution story rather than a policy beneficiary. The contrarian view is that the headline positives are already priced into hydrogen sentiment, while the balance-sheet burden remains underappreciated.

Key Decisions for Investors

• No standalone long in H2APEX at this stage; treat it as a financing/event-risk name until there is evidence of positive project gross margin or a cleaner funding path. Time horizon: 1-3 months.
• Long LIN or AIR.PA vs. short NEL.OL / ITM.L on a 3-6 month basis: incumbents with hydrogen exposure can monetize regulated demand without the same dilution risk, while pure-play electrolyzer vendors remain cash-burning price takers.
• Use any post-release strength to fade speculative hydrogen beta via a short basket in NEL.OL and ITM.L; thesis is that quota support benefits project developers more than equipment suppliers. Stop if order intake or margin guidance inflects materially higher on the next print.
• Set an alert for any H2APEX equity raise, bridge financing, or project-level funding announcement; if announced, expect 10-20% downside in the equity on dilution fears and reassess only after terms are visible.